A technology evaluation of the Onyx Frontier drug-eluting stent.
Coronary artery disease
Onyx frontier
drug-eluting stent
percutaneous coronary intervention
zotarolimus
Journal
Expert opinion on drug delivery
ISSN: 1744-7593
Titre abrégé: Expert Opin Drug Deliv
Pays: England
ID NLM: 101228421
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
medline:
19
6
2023
pubmed:
19
5
2023
entrez:
19
5
2023
Statut:
ppublish
Résumé
Onyx Frontier We hereby review the principal design features of Onyx Frontier, highlighting differences and similarities with other currently available drug-eluting stents. In addition, we focus on the refinements of this newest platform as compared with previous ZES versions, including the attributes yielding its exceptional crossing profile and deliverability. The clinical implications related to both its newest and inherited characteristics will be discussed. The nuances of the latest Onyx Frontier, together with the continuous refinement previously witnessed throughout the development of ZES, lead to a latest generation device ideal for a diverse spectrum of clinical and anatomical scenarios. In particular, its peculiarities will be of benefit in the settings often offered by a progressively aging population, such as high bleeding risk patients and complex coronary lesions.
Identifiants
pubmed: 37203200
doi: 10.1080/17425247.2023.2216449
doi:
Substances chimiques
zotarolimus
H4GXR80IZE
Cardiovascular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM